Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
106M
-
Number of holders
-
119
-
Total 13F shares, excl. options
-
43.6M
-
Shares change
-
-5.83M
-
Total reported value, excl. options
-
$82.9M
-
Value change
-
-$16.9M
-
Put/Call ratio
-
4.13
-
Number of buys
-
60
-
Number of sells
-
-94
-
Price
-
$1.90
Significant Holders of Amylyx Pharmaceuticals, Inc. - COMMON STOCK (AMLX) as of Q2 2024
201 filings reported holding AMLX - Amylyx Pharmaceuticals, Inc. - COMMON STOCK as of Q2 2024.
Amylyx Pharmaceuticals, Inc. - COMMON STOCK (AMLX) has 119 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.6M shares
of 106M outstanding shares and own 41.03% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (4.22M shares), AQR CAPITAL MANAGEMENT LLC (3.34M shares), BlackRock Inc. (2.67M shares), GOLDMAN SACHS GROUP INC (2.61M shares), Almitas Capital LLC (1.9M shares), Alyeska Investment Group, L.P. (1.82M shares), MILLENNIUM MANAGEMENT LLC (1.54M shares), 683 Capital Management, LLC (1.5M shares), Boxer Capital, LLC (1.5M shares), and CITADEL ADVISORS LLC (1.34M shares).
This table shows the top 119 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.